NCT00004862: Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia |
|
|
| Completed | 1 | 24 | US | filgrastim, oblimersen sodium, cytarabine, fludarabine phosphate | National Cancer Institute (NCI) | Leukemia | 12/01 | | | |
NCT00039117: Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia |
|
|
| Completed | 1 | 32 | US | oblimersen sodium, augmerosen, G3139, G3139 bcl-2 antisense oligodeoxynucleotide, Genasense, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, daunorubicin hydrochloride, Cerubidin, Cerubidine, daunomycin hydrochloride, daunorubicin, RP-13057, laboratory biomarker analysis, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia | 09/03 | | | |
